Sven Berkmann1, Michel Roethlisberger2, Beat Mueller3, Mirjam Christ-Crain4, Luigi Mariani2, Egbert Nitzsche5, Freimut Juengling6,7. 1. Department of Neurosurgery, Kantonsspital Aarau, Tellstrasse, 5001, Aarau, CH, Switzerland. sven.berkmann@ksa.ch. 2. Department of Neurosurgery, Universitaetsspital Basel, Basel, CH, Switzerland. 3. Division of Endocrinology, Diabetology and Metabolism, Univ. Department of Medicine, Kantonsspital Aarau, Aarau, CH, Switzerland. 4. Division of Endocrinology, Diabetology and Metabolism, Univ. Department of Medicine, Universitaetsspital Basel, Basel, CH, Switzerland. 5. Department of Nuclear Medicine, Kantonsspital Aarau, Aarau, CH, Switzerland. 6. Department of Nuclear Medicine, St. Claraspital, Basel, CH, Switzerland. 7. Medical Faculty, University Bern, Bern, CH, Switzerland.
Abstract
PURPOSE: 11-C-methionine (MET)-positron emission tomography (PET) as an adjunct to magnetic resonance imaging (MRI) has been proposed as a suitable molecular imaging modality for localizing pituitary adenomas in Cushing's disease. 18-F-Fluoroethyl-L-tyrosine (FET)-PET, which is more widely available has not yet been reported in this context. METHODS: Retrospective double-center cohort study on 15 patients who underwent transsphenoidal surgery for biochemically proven Cushing's disease between 2011 and 2019. Preoperative MET-PET/MRI and/or FET-PET/MRI were compared with intraoperative and histopathological examinations using the Mann Whitney U test and the Fisher's Exact test, along with positive predictive value calculations. RESULTS: Fifteen patients were included, with a mean age of 47.2 (18-69) years. Six patients received either a MET-PET/MRI or a FET-PET/MRI and 3 patients both exams, respectively. 67% of the tumors were detected by MRI (MET-PET-group [56%]; FET-PET-group [78%]). All tumors were microadenomas with a mean adenoma volume of 0.19 cm3 (0.02-0.78), all of which displayed a circumscribed pathological FET- and/or MET-uptake. FET-PET/MRI results positively correlated with the localization of the tumor confirmed intraoperatively and histopathologically in all cases, resulting in a sensitivity and specificity of FET-PET/MRI for tumor localization of 100% (95% CI 66.37-100%). One MET-PET/MRI suggested a localization contralateral to the expected spot. The sensitivity and specificity of MET-PET for tumor localization hence was 89% (95% CI 51.75-99.72%). CONCLUSIONS: Preoperative hybrid FET-PET/MRI and MET-PET/MRI have a high predictive value in localizing corticotroph adenoma for selective adenomectomy in Cushing's disease.
PURPOSE: 11-C-methionine (MET)-positron emission tomography (PET) as an adjunct to magnetic resonance imaging (MRI) has been proposed as a suitable molecular imaging modality for localizing pituitary adenomas in Cushing's disease. 18-F-Fluoroethyl-L-tyrosine (FET)-PET, which is more widely available has not yet been reported in this context. METHODS: Retrospective double-center cohort study on 15 patients who underwent transsphenoidal surgery for biochemically proven Cushing's disease between 2011 and 2019. Preoperative MET-PET/MRI and/or FET-PET/MRI were compared with intraoperative and histopathological examinations using the Mann Whitney U test and the Fisher's Exact test, along with positive predictive value calculations. RESULTS: Fifteen patients were included, with a mean age of 47.2 (18-69) years. Six patients received either a MET-PET/MRI or a FET-PET/MRI and 3 patients both exams, respectively. 67% of the tumors were detected by MRI (MET-PET-group [56%]; FET-PET-group [78%]). All tumors were microadenomas with a mean adenoma volume of 0.19 cm3 (0.02-0.78), all of which displayed a circumscribed pathological FET- and/or MET-uptake. FET-PET/MRI results positively correlated with the localization of the tumor confirmed intraoperatively and histopathologically in all cases, resulting in a sensitivity and specificity of FET-PET/MRI for tumor localization of 100% (95% CI 66.37-100%). One MET-PET/MRI suggested a localization contralateral to the expected spot. The sensitivity and specificity of MET-PET for tumor localization hence was 89% (95% CI 51.75-99.72%). CONCLUSIONS: Preoperative hybrid FET-PET/MRI and MET-PET/MRI have a high predictive value in localizing corticotroph adenoma for selective adenomectomy in Cushing's disease.
Authors: Y Sammy Woo; Andrea M Isidori; Winnie Z Wat; Gregory A Kaltsas; Fari Afshar; Ian Sabin; Paul J Jenkins; John P Monson; G Michael Besser; Ashley B Grossman Journal: J Clin Endocrinol Metab Date: 2005-05-10 Impact factor: 5.958
Authors: J Lindholm; S Juul; J O Jørgensen; J Astrup; P Bjerre; U Feldt-Rasmussen; C Hagen; J Jørgensen; M Kosteljanetz; L Kristensen; P Laurberg; K Schmidt; J Weeke Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: Sylvie Salenave; Blandine Gatta; Sylvie Pecheur; François San-Galli; André Visot; Pierre Lasjaunias; Patrick Roger; Jérôme Berge; Jacques Young; Antoine Tabarin; Philippe Chanson Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon Journal: Cancer Date: 2004-08-01 Impact factor: 6.860
Authors: W A Bashari; D Gillett; J MacFarlane; A S Powlson; A G Kolias; R Mannion; D J Scoffings; I A Mendichovszky; J Jones; H K Cheow; O Koulouri; M Gurnell Journal: Pituitary Date: 2022-06-06 Impact factor: 3.599